Yuyu Pharma to attend 'CPHI Worldwide 2023'

In particular, Yuyu will focus on promoting projects currently under development, such as a reduced sized Dutasteride and Dutasteride-Tamsulosin combination drug. These projects are being developed with the goal of entering the U.S. and European Benign Prostate Hyperplasia  In particular, Yuyu will focus on promoting projects currently under development, such as a reduced sized Dutasteride and Dutasteride-Tamsulosin combination drug. These projects are being developed with the goal of entering...

SEOUL, South Korea, 18/10/2023 (informazione.news - comunicati stampa - scienza e tecnologia)

In particular, Yuyu will focus on promoting projects currently under development, such as a reduced sized Dutasteride and Dutasteride-Tamsulosin combination drug. These projects are being developed with the goal of entering the U.S. and European Benign Prostate Hyperplasia 

Danny Kang , Export Manager at Yuyu said "As always, we look forward to having active discussions with partners at our CPHI booth. And hope to meet new potential partners as well" 

With over 80 years in the healthcare industry, Yuyu Pharma (KRX: 000220) is a rapidly scaling global pharmaceutical company founded in Seoul, South Korea . Yuyu is committed to developing innovative therapeutics in the areas of neurology, dermatology, urology, and ophthalmology. Yuyu's Mission is to improve the quality of life and enhance well-being for all individuals by developing innovative healthcare products and services.

Photo - https://mma.prnewswire.com/media/2249315/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/yuyu-pharma-to-attend-cphi-worldwide-2023-301959839.html